Collegium Pharmaceutical (NASDAQ:COLL) posts in line Q3 2026 sales and full year revenue guidance above estimates, stock soars
Collegium Pharmaceutical reported Q3 2026 revenue of $216.3M, in line with estimates, and adjusted EPS of $1.96, beating estimates by 5.6%. The company reconfirmed its full-year revenue guidance of $840M and raised EBITDA guidance to $457.5M, above estimates. Operating margin decreased to 13.3% from 29.7% YoY.
How this was made

The 30-second read
Why it matters
The earnings beat and reaffirmed guidance suggest strong pipeline progress, likely attracting growth‑oriented investors.
Market read
Fresh earnings data provides a clear catalyst for short‑term trading decisions on COLL.
What to watch
Potential upcoming regulatory or clinical trial milestones could temper the rally if not met.
Background
Collegium Pharmaceutical is a small‑cap biotech that recently released its Q3 2026 earnings.
Ticker impact
Collegium Pharmaceutical reported Q3 2026 revenue of $216.3M, beating estimates, and reaffirmed full-year revenue guidance of $840M.
upward pressure as the market prices in the earnings beat and raised guidance
The beat on revenue and EPS, plus higher‑than‑expected full‑year guidance, are fresh primary disclosures that typically drive buying interest.
Market effects
Biotech and specialty pharma sector may see modest uplift as the beat highlights demand for niche therapeutics.
U.S. small‑cap biotech segment could see increased buying pressure.
Limited to investors focused on U.S. biotech; no broad macro impact.
Counterpoint
If the beat is already priced in, the stock could face short‑covering pull‑back.
Key entities
- companyCollegium Pharmaceutical
U.S. listed biotech (NASDAQ:COLL) reporting Q3 2026 results.


